Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Fresenius

Drug and asset intelligence for Fresenius with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
4
Catalysts
0
Stage
Development stage unavailable

Recent signals(4)

RegulatoryAugust 6, 2026

Fresenius Kabi Recalls Morphine Sulfate Injection Due to Labeling Error

Fresenius Kabi is recalling one lot of Morphine Sulfate Injection due to a labeling mix-up that could lead to medication errors.

RegulatoryAugust 2, 2026

Fresenius Kabi's Ondansetron Hydrochloride Preservative Free Receives AP Status

Fresenius Kabi USA's application for Ondansetron Hydrochloride Preservative Free has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryAugust 1, 2026

Fresenius Kabi's Ondansetron Hydrochloride ANDA076974 Receives AP Status

Fresenius Kabi USA has received an Abbreviated New Drug Application (ANDA) approval status for Ondansetron Hydrochloride.

StrategyJuly 25, 2026

Fresenius Kabi USA receives AP status for Dexamethasone Sodium Phosphate ANDA209192

Fresenius Kabi USA's ANDA209192 for Dexamethasone Sodium Phosphate has received Abbreviated Approval (AP) status.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Therapeutic areas

Antiemetic →
Corticosteroid →
Endocrinology →
Oncology →
Opioid →
Pain Management →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.